De Novo Donor-Specific HLA Antibody Formation in Two Patients with Crigler-Najjar Syndrome Type i Following Human Hepatocyte Transplantation with Partial Hepatectomy Preconditioning

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 1021-1030

  Jorns, C ^a   Nowak, G ^a   Nemeth, A ^a   Zemack, H ^a   Mork L M ^a   Johansson, H ^a   Gramignoli, R ^a   Watanabe, M ^a   Karadagi, A ^a   Alheim, M ^a   Hauzenberger, D ^a   Van Dijk, R ^b   Bosma, P J ^b   Ebbesen, F ^c   Szakos, A ^a   Fischler, B ^a   Strom, S ^a   Ellis, E ^a   Ericzon, B G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CASPASE 3; CASPASE 7; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; GLUCURONOSYLTRANSFERASE 1A1; HLA ANTIBODY; PHENOBARBITAL; HLA ANTIGEN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHILD; CONTROLLED STUDY; CRIGLER NAJJAR SYNDROME TYPE I; FEMALE; GENE MUTATION; GRAFT FAILURE; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER REGENERATION; MALE; PARTIAL HEPATECTOMY; PARTIAL HEPATECTOMY PRECONDITIONING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STOP CODON; ADULT; ADVERSE EFFECTS; CRIGLER-NAJJAR SYNDROME; DONOR; GRAFT REJECTION; IMMUNOLOGY; INFANT; LIVER CELL; LIVER RESECTION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PROGNOSIS; TRANSPLANTATION;

ADOLESCENT; ADULT; ANTIBODY FORMATION; CHILD; CRIGLER-NAJJAR SYNDROME; FEMALE; GRAFT REJECTION; HEPATECTOMY; HEPATOCYTES; HLA ANTIGENS; HUMANS; INFANT; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; TISSUE DONORS;

EID: 84959489763     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13487     Document Type: Article

References (20)

1. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH., Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006; 165: 306-319.
2. Jorns C, Ellis EC, Nowak G, et al., Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med 2012; 272: 201-223.
3. Gupta S, Johnstone R, Darby H, Selden C, Price Y, Hodgson HJ., Transplanted isolated hepatocytes: Effect of partial hepatectomy on proliferation of long-term syngeneic implants in rat spleen. Pathology 1987; 19: 28-30.
4. Taner T, Stegall MD, Heimbach JK., Antibody-mediated rejection in liver transplantation: Current controversies and future directions. Liver Transpl 2014; 20: 514-527.
5. Campbell PM, Senior PA, Salam A, et al., High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7: 2311-2317.
6. Gramignoli R, Tahan V, Dorko K, et al., Rapid and sensitive assessment of human hepatocyte functions. Cell Transplant 2014; 23: 1545-1556.
7. Alheim M, AlMahri A, Nilsson J, Tyden G, Holgersson J., The outcome of the endothelial precursor cell crossmatch test in lymphocyte crossmatch positive and negative patients evaluated for living donor kidney transplantation. Hum Immunol 2013; 74: 1437-1444.
8. Seppen J, Bakker C, de Jong B, et al., Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther 2006; 13: 1085-1092.
9. Puppi J, Strom SC, Hughes RD, et al., Improving the techniques for human hepatocyte transplantation: Report from a consensus meeting in London. Cell Transplant 2012; 21: 1-10.
10. Grossman M., A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
11. Baccarani U, Adani GL, Sanna A, et al., Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Int 2005; 18: 750-754.
12. Meyburg J, Hoerster F, Schmidt J, Poeschl J, Hoffmann GF, Schenk JP., Monitoring of intraportal liver cell application in children. Cell Transplant 2010; 19: 629-638.
13. Clavien PA, Camargo CA Jr, Croxford R, Langer B, Levy GA, Greig PD., Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg 1994; 220: 109-120.
14. Debonera F, Krasinkas AM, Gelman AE, et al., Dexamethasone inhibits early regenerative response of rat liver after cold preservation and transplantation. Hepatology 2003; 38: 1563-1572.
15. Hayashi H, Beppu T, Sugita H, et al., Serum HGF and TGF-beta1 levels after right portal vein embolization. Hepatol Res 2010; 40: 311-317.
16. Fox IJ, Chowdhury JR, Kaufman SS, et al., Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-1426.
17. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P., Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33: 139-146.
18. Erps LT, Ritter JK, Hersh JH, Blossom D, Martin NC, Owens IS., Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 1994; 93: 564-570.
19. Allen KJ, Mifsud NA, Williamson R, Bertolino P, Hardikar W., Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl 2008; 14: 688-694.
20. Bumgardner GL, Li J, Heininger M, Ferguson RM, Orosz CG,. In vivo immunogenicity of purified allogeneic hepatocytes in a murine hepatocyte transplant model. Transplantation 1998; 65: 47-52.